Agatsa, a medtech startup that specialises in cardiac issue diagnostics, has raised Rs 125 million to expand its operations and product portfolio.
Its goal is to transform India’s cardiac care business.
Agatsa has established itself as India’s first B2C med-tech brand, and it is now pursuing B2B partnerships with large hospitals and telehealth firms, according to a press release.
With CE and FDA certification in the works, Agatsa is preparing to expand into the US and European markets. Agatsa invented the world’s first pocket 12-lead ECG equipment, which is 99 percent accurate and is used by both doctors and heart patients in India to diagnose and detect cardiac abnormalities quickly. The device is simple to operate, inexpensive, and small enough to fit in anyone’s pocket.